Skip to Main Content

Paper Details

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
Nat Biotechnol
24
2022
ACE2, B cell, B cell receptor, COVID, S) protein, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 spike, angiotensin-converting enzyme 2, coronavirus disease 2019, severe, severe acute respiratory syndrome coronavirus
Author NameAffiliation
James E CroweVanderbilt University Medical Center
James E CroweVanderbilt University Medical Center
James E CroweVanderbilt University Medical Center
Robert H CarnahanVanderbilt University Medical Center
Robert H CarnahanVanderbilt University Medical Center
Jason S McLellanThe University of Texas at Austin
Ivelin S GeorgievVanderbilt University Medical Center
Ivelin S GeorgievVanderbilt University Medical Center
Ivelin S GeorgievVanderbilt Institute for Infection, Vanderbilt University Medical Center
Ivelin S GeorgievVanderbilt University
Ivelin S GeorgievCenter for Structural Biology, Vanderbilt University
Ivelin S GeorgievVanderbilt University Medical Center
  • 1 - 12

Datasets

Release 1.2